Research progress of negative costimulator B7-H4 in urologic tumors.
- Author:
Yan TAO
1
;
Mei HONG
1
Author Information
1. Institute of Urology, Second Hospital of Lanzhou University, Gansu Provincial Key Laboratory of Urological Diseases, Gansu Nephro-Urological Clinical Center, Lanzhou 730030, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Interleukin-2;
Urologic Neoplasms;
V-Set Domain-Containing T-Cell Activation Inhibitor 1
- From:
Journal of Zhejiang University. Medical sciences
2014;43(4):480-485
- CountryChina
- Language:Chinese
-
Abstract:
B7-H4 is a recently-identified member of B7 costimulation superfamily. B7-H4 serves as an inhibitory modulator of T cell response through suppressing the proliferation, activation, and cytokine production of T cells. B7-H4 is found to be abnormally expressed in multiple human tumors. Many studies have shown that B7-H4 expression is closely related to the progression and prognosis of urologic tumors. Investigation of B7-H4 function will provide new strategies for diagnosis and immunotherapy of urologic tumors. This article reviews the recent progress of B7-H4 research in urologic tumors.
